The new test enables physicians to accurately differentiate between bacterial and viral infections, thus supporting fast and more-informed treatment and patient management decisions.

This pioneering solution is now available on the DiaSorin LIAISON® XL analyzer.
LIAISON® MeMed BV®

The easy, high-quality way to enhance clinical decision-making while fighting the problem of antimicrobial resistance

LIAISON® MeMed BV® delivers fast diagnostic differentiation between bacterial and viral infections in a single procedure, helping transform the treatment of infectious diseases.
Accurately distinguishes between bacterial and viral infections

DiaSorin’s newest high-throughput, high-quality chemiluminescent assay easily identifies the source of a patient’s infection using the LIAISON® XL automatic analyzer.
**Bacterial or viral:**
Since bacterial and viral infections are clinically indistinguishable, physicians are often challenged when deciding whether or not to treat an illness with antibiotics. LIAISON® MeMed BV® provides host immune response information, helping physicians make more informed treatment decisions.

**Antibiotics are the most misused drugs:**

- **Antibiotic overuse** (1-4) - 50%
- **Antibiotic underuse** (5-7) - 20%

**Conventional tests are often insufficient...**
- Multi-step workflow required
- Prolonged time to results
- Risk of antibiotic misuse
- Limited sensitivity and specificity
- Uncertainty regarding severity
- Lack of automated testing procedures

**Three biomarkers + machine learning = better patient care**

From a simple serological sample, LIAISON® MeMed BV® automatically measures, analyzes and integrates the levels of three host immune proteins into a single and simple score, showing the likelihood of a bacterial immune response or co-infection versus a likely viral immune response.

The computational signature for accurate diagnosis of acute bacterial (or mixed) versus viral infections was developed and validated on >20,000 cohort of patients. (8-12)

**The numeric score falls within discrete interpretation ranges based on the increasing likelihood of bacterial infection**
The clinical performances of LIAISON® MeMed BV® has been confirmed in validation based on testing with patients with signs and symptoms suggestive of acute bacterial or viral infection. Measures of Sensitivity, Specificity and Negative Predictive Value (NPV) have been calculated by considering a bacterial result as positive and a viral/other result as negative.

**Performances**

<table>
<thead>
<tr>
<th>Metric</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sensitivity</td>
<td>96.3%</td>
</tr>
<tr>
<td>Specificity</td>
<td>91.3%</td>
</tr>
<tr>
<td>NPV</td>
<td>99.5%</td>
</tr>
</tbody>
</table>

*Data based on secondary endpoint analysis*
Pairing powerful yet simple chemiluminescence immunoassay (CLIA) analysis with high sensitivity and precision, DiaSorin fully supports clinical decision making by delivering reliable and easy-to-interpret scientific data in less than 1 hour. Put your trust in our value-based care solution and benefit from the speed and precision of DiaSorin diagnostic excellence.

LIAISON® MeMed BV® – empowering patient care while fighting the problem of antimicrobial resistance.

References:
2. Linder JA et al.; JAMA. 2001
3. Cadieux G et al.; CMAJ. 2007
5. Battleman DS et al.; Arch Intern Med. 2002
7. Craig JC et al.; BMJ. 2010
8. Oved K et al.; PLoS One. 2015
9. van Houten CB et al.; Lancet Infect Dis. 2017
10. Srugo I et al.; Pediatrics. 2017
12. Stein M et al.; Diagn Microbiol Infect Dis. 2018

Product availability subject to required regulatory approval